XML 20 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jul. 03, 2020
Jan. 03, 2020
Current assets:    
Cash and cash equivalents $ 527,143 $ 266,501
Short-term investments 685,895 585,742
Trade receivables, net 121,080 119,073
Inventory 16,608 12,886
Prepaid expenses and other current assets 43,937 26,988
Total current assets 1,394,663 1,011,190
Long-term investments 327,141 536,385
Property and equipment, net 52,323 48,892
Deferred tax assets, net 148,235 172,374
Goodwill 63,684 63,684
Other long-term assets 60,502 53,145
Total assets 2,046,548 1,885,670
Current liabilities:    
Accounts payable 9,103 11,581
Accrued compensation and benefits 33,156 37,364
Accrued clinical trial liabilities 39,940 38,777
Rebates and fees due to customers 16,957 18,719
Accrued collaboration liabilities 10,695 11,856
Other current liabilities 32,830 24,449
Total current liabilities 142,681 142,746
Long-term portion of deferred revenues 15,003 6,596
Long-term portion of operating lease liabilities 48,334 48,011
Other long-term liabilities 7,206 2,347
Total liabilities 213,224 199,700
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 308,886 and 304,831 at June 30, 2020 and December 31, 2019, respectively 309 305
Additional paid-in capital 2,269,093 2,241,947
Accumulated other comprehensive income 7,840 3,069
Accumulated deficit (443,918) (559,351)
Total stockholders’ equity 1,833,324 1,685,970
Total liabilities and stockholders’ equity $ 2,046,548 $ 1,885,670